Tumour necrosis factor increases tumour uptake of Co-administered antibody-carboxypeptidase G2 conjugate

European Journal of Cancer

Volumn 29, Issue 8, 1993, Pages 1177-1183

  Melton, R G ^a   Sherwood, R F ^a   Rowland, J A ^b   Pietersz, G A ^b   McKenzie, I F C ^b  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b AUSTIN RESEARCH INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY CARBOXYPEPTIDASE G2 CONJUGATE; INTERLEUKIN 2; METHOTREXATE; MONOCLONAL ANTIBODY; RECOMBINANT HUMAN TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR;

ANIMAL; CARBOXYPEPTIDASES; COMPARATIVE STUDY; ELECTROPHORESIS, POLYACRYLAMIDE GEL; IMMUNOGLOBULIN G; IMMUNOTOXINS; INTERLEUKIN-2; MICE; MICE, INBRED STRAINS; RECOMBINANT FUSION PROTEINS; SUPPORT, NON-U.S. GOV'T; THYMOMA; THYMUS NEOPLASMS; TIME FACTORS; TISSUE DISTRIBUTION; TUMOR NECROSIS FACTOR;

EID: 0027212228     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(05)80311-9     Document Type: Article

References (24)

1. A cytotoxic agent can be generated selectively at cancer sites
2. Anti-tumour effects of antibody-alkaline phosphatase conjugates in combinaton with etoposide phosphate
3. Antibody directed enzyme prodrug therapy (ADEPT)—Clinical Report
4. Enhancement of the in vitro and in vivo antitumour activities of phosphorylated mitomycin C and etoposide derivatives by monoclonal antibody-alkaline phosphatase conjugates
5. In vitro and in vivo activities of monoclonal antibody-alkaline phosphatase conjugates in combination with phenol mustard phosphate
6. Antineoplastic glucuronide prodrug treatment of human tumour cells targeted with a monoclonal antibody enzyme conjugate
7. Antibody-penicillin-V-amidase conjugates kill antigen-positive tumor cells when combined with doxorubicin phenoxyacetamide
8. A novel targeted delivery system utilizing a cephalosporin-oncolytic prodrug activated by an antibody beta-lactamase conjugate for the treatment of cancer
9. Antigenic heterogeneity of surgically removed primary and autologous metastatic human melanoma lesions
10. Definition of antigenic heterogeneity and modulation among human mammary carcinoma cell populations using monoclonal antibodies to tumour-associated antigens
11. Heterogeneity of cell surface antigen expression of human small cell lung cancer detected by monoclonal antibodies
12. Inactivation and clearance of an anti-CEA carboxypeptidase G2 conjugate in blood after localisation in a xenograft model
13. Increased anti-tumour effect of immunoconjugates and tumour necrosis factor in vivo
14. Effect of tumour necrosis factor on the anti-tumour efficacy and toxicity of aminopterin-monoclonal antibody conjugates: parameters for optimisation of therapy
15. Enhanced tumour uptake of macromolecules induced by a novel vasoactive interleukin-2 immunoconjugate
16. The diffusion of a tumour-specific monoclonal antibody in lymphoma infiltered spleen
17. Cellular distribution of monoclonal antibody in human tumours after i.v. administration
18. Influence of recombinant tumour necrosis factor-alpha on blood flow and antibody localisation in human tumour xenografts in nude mice
19. Monoclonal antibodies to murine Ly-2.1 surface antigen
20. Purification and properties of carboxypeptidase G2 from Pseudomonas sp. strain RS16. Use of a novel triazine dye affinity model
21. 2
22. A rapid and sensitive method of quantification of microgram quantities of protein using the principle of protein-dye binding
23. The preparation of 131I-labelled human growth hormone of high specific radioactivity
24. Construction and chemotherapeutic potential of carboxypeptidase A/monoclonal antibody conjugate